EvoMG-DN · Evolutionary Medical Genomics Doctoral Network
Horizon Europe — Marie Skłodowska-Curie Actions
- Duration
- 2026-01-01 → 2029-12-31
- EU contribution
- €4,601,373
- Participants
- 22
- Scheme
- HORIZON-TMA-MSCA-DN
Lines connect the coordinator with its partners.
Project objective
The Evolutionary Medical Genomics Doctoral Network (EvoMG-DN) pioneers an integrative approach combining Evolutionary Medicine and Medical Genomics to address critical health challenges. By combining evolutionary insights with state-of-the-art genomic tools, EvoMG-DN seeks to establish EvoMG as a structured and impactful discipline in Europe. The network aims to train the next generation of interdisciplinary researchers to unlock the full potential of evolutionary genomic approaches in healthcare.EvoMG-DN pursues three overarching objectives: (i) foster interdisciplinary synergy by uniting EvoMG researchers from diverse fields to catalyze innovation in methodologies and tools; (ii) create a cohesive training framework, equipping doctoral candidates (DCs) with expertise in EvoMG applications through structured training and collaboration; and (iii) advance evolution-informed clinical applications, such as adaptive cancer therapies.The research program is organized into three scientific work packages: WP1 explores evolutionary insights into ageing and age-related diseases; WP2 focuses on tumor evolution and acquisition of resistance in cancer therapies; and WP3 addresses pathogen evolution, antibiotic resistance and interactions with the immune system. These are underpinned by core methodological pillars, which include comparative functional genomics, genetic diversity analysis, mathematical modeling and machine learning, and the use of unconventional model organisms.Through interdisciplinary secondments, tailored mentoring, and advanced training modules, EvoMG-DN empowers DCs to bridge disciplines and develop actionable solutions to global health challenges. By formalizing EvoMG methodologies and advancing clinical applications, EvoMG-DN aims to solidify Europe’s leadership in biomedical research and deliver long-lasting societal impact.
Original text from CORDIS.
Participants
- FUNDACIO CENTRE DE REGULACIO GENOMICA · BarcelonaCoordinatorSpain
- BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACION · BARCELONASpain
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisFrance
- CHALMERS TEKNISKA HOGSKOLA AB · GoteborgSweden
- DUKE UNIVERSITY · Durham NcUnited States
- ECOLE NORMALE SUPERIEURE · ParisFrance
- EUROPEAN MOLECULAR BIOLOGY ORGANIZATION · GeneveSwitzerland
- FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA · LisboaPortugal
- FRIEDRICH-SCHILLER-UNIVERSITÄT JENA · JENAGermany
- FUNDACAO GIMM - GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE · LISBOAPortugal
- FUNDACIO D'ESTUDIS I RECERCA ONCOLOGICA (FERO) · BarcelonaSpain
- INSTITUT PASTEUR · ParisFrance
- INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG · LondonUnited Kingdom
- LEIBNIZ-INSTITUT FUR ALTERNSFORSCHUNG - FRITZ-LIPMANN-INSTITUT EV (FLI) LEIBNIZ INSTITUTE ON AGING - FRITZ LIPMANN INSTITUTE EV (FLI) · JenaGermany
- Mashauri Limited · AddlestoneUnited Kingdom
- Microomics Systems S.L. · BarcelonaSpain
- Nonacus Ltd · WalsallUnited Kingdom
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE · CAMBRIDGEUnited Kingdom
- UNIVERSIDAD POMPEU FABRA · BarcelonaSpain
- UNIVERSITAT DE BARCELONA · BarcelonaSpain
- UNIVERSITE PARIS CITE · ParisFrance
- UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN · DublinIreland
Links
Data: CORDIS, © European Union